AX-0810, an experimental therapy for biliary atresia and other cholestatic diseases, is expected to enter clinical testing by early…
Articles by Marisa Wexler, MS
Most people with chronic hepatitis B enrolled in a Phase 2b clinical trial were eligible to discontinue their use…
Note: This story was updated Aug. 20, 2024, to correct that Livdelzi is not a first-in-class therapy for primary…
Two Phase 3 clinical trials testing pegozafermin in people with metabolic dysfunction-associated steatohepatitis (MASH), a severe manifestation of fatty…
The U.S. Food and Drug Administration (FDA) has given Gigagen the go-ahead to start clinical testing of GIGA-2339, its…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IN016, an experimental therapy Innorna is…
Pemvidutide, Altimmune’s experimental therapy, significantly reduced liver fat and inflammation, as well as body weight, among overweight or…
NGM Biopharmaceuticals has raised $122 million in financing, which the California-based company will use to help launch a planned…
The American Liver Foundation (ALF) has launched two projects that aim to improve care for people with metabolic…
Six months of treatment with a high dose of bexotegrast, Pliant Therapeutics’ oral candidate, was superior to a placebo…